Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27216274

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Jul
First author
Eichhorst B

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jul;17(7):852-854. doi: 10.1016/S1470-2045(16)30118-8.
    note
    Source null
    related pmid
    27216275
    relationship
    Comment in

Authors and identifiers

  1. name
    Eichhorst B
    type
    Author
  2. name
    Fink AM
    type
    Author
  3. name
    Bahlo J
    type
    Author
  4. name
    Busch R
    type
    Author
  5. name
    Kovacs G
    type
    Author
  6. name
    Maurer C
    type
    Author
  7. name
    Lange E
    type
    Author
  8. name
    Köppler H
    type
    Author
  9. name
    Kiehl M
    type
    Author
  10. name
    Sökler M
    type
    Author
  11. name
    Schlag R
    type
    Author
  12. name
    Vehling-Kaiser U
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Eichhorst B
    type
    Author
  2. name
    Fink AM
    type
    Author
  3. name
    Bahlo J
    type
    Author
  4. name
    Busch R
    type
    Author
  5. name
    Kovacs G
    type
    Author
  6. name
    Maurer C
    type
    Author
  7. name
    Lange E
    type
    Author
  8. name
    Köppler H
    type
    Author
  9. name
    Kiehl M
    type
    Author
  10. name
    Sökler M
    type
    Author
  11. name
    Schlag R
    type
    Author
  12. name
    Vehling-Kaiser U
    type
    Author
bibliography ids
  1. nci-bib-d4266ca7ceba2f75d70b02ed
book metadata
content sha256
97ef9b516a9de2bceb85b0e46b89fe4819ce8d72e406f53be4c2f68ae565a0ff
document type
citation
dois
  1. 10.1016/S1470-2045(16)30051-1
electronic publication date
display
2016 May 20
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27216274
immutable id
pubmed:27216274@97ef9b516a9de2bceb85b0e46b89fe4819ce8d72e406f53be4c2f68ae565a0ff
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
928-942
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jul;17(7):852-854. doi: 10.1016/S1470-2045(16)30118-8.
    note
    Source null
    related pmid
    27216275
    relationship
    Comment in
outcomes validated
false
pmid
27216274
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
70bda7dbb77d3af8a760f8ee1b245da9fc38811018ceb99e82ddddc14adc48bd
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Jul
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27216274/
title
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Preserved source evidence · Not medical advice